Many patients with B12 deficiency, especially those with pernicious anemia, have difficulty clearing cyanide
Blusztajn, Jan Krzysztof
This rapidly growing field is continuously uncovering new therapeutic peptides designed to target specific diseases and conditions, offering hope for more personalized and effective treatments
Children presenting neurological signs or symptoms, those unable to take oral medication, individuals with known malabsorption syndromes, infants under 6 months old, and patients using medications that may interfere with vitamin B12 absorption are typically treated with a parenteral protocol (1)
AOD 9604 is an investigational peptide that requires a licensed medical provider, prescription, and clinical oversight
References Heffernan, M., et al